Filing Flows › Silicon Laboratories (SLAB) › Takeover & LBO
Is Silicon Laboratories (SLAB) a takeover target?
A leveraged buyout does not work for Silicon Laboratories on its latest figures: it has no positive EBITDA to borrow against (−$19.2M over the last 12 months, on revenue of $856M). Historically 5.3% of companies with its figures were bought within a year (1.06× the average). Latest signal (2026-03-27): Merger proxy (DEFM14A).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Silicon Laboratories' EBITDA over the last 12 months was −$19.2M on revenue of $856M, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 30% over the share price before the deal (the middle half 12% to 31%), according to the 14 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Silicon Laboratories would cost about $288.21 a share, $9.6B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 12% | $248.30 | $8.2B |
| Median | 30% | $288.21 | $9.6B |
| High end (a quarter paid more) | 31% | $290.43 | $9.6B |
The odds, from history
Historically 5.3% of companies with its figures were bought within a year (1.06× the average). Its figures put it in decile 6 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Rumors and deal signals
- 2026-03-27 · DEFM14A · Merger proxy (DEFM14A)
Silicon Laboratories' latest quarter
Silicon Laboratories, Q2 2026: revenue $228M (+18% year over year), operating margin -4.7%, net loss $10.6M, operating cash flow −$14.5M. The chart follows the revenue to costs, profit and cash.
Questions
Is Silicon Laboratories being acquired?
The latest signal on file is from 2026-03-27: Merger proxy (DEFM14A). A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Silicon Laboratories?
A leveraged buyout does not work for Silicon Laboratories on its latest figures: it has no positive EBITDA to borrow against (−$19.2M over the last 12 months, on revenue of $856M). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Silicon Laboratories cost?
Takeovers in its sector paid a median premium of 30% over the share price before the deal (the middle half 12% to 31%), according to the 14 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Silicon Laboratories would cost about $288.21 a share, $9.6B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.